Some CRPC treatments are used only in men whose tumors have certain characteristics that make the therapy more likely to be effective. Men whose tumors express the protein PSMA may receive the radiopharmaceutical Lu-177 PSMA, which binds to and destroys PSMA-positive cells. Those whose tumors have defective DNA damage repair benefit from treatment with the immune checkpoint inhibitor drug pembrolizumab and PARP inhibitors, namely olaparib, rucaparib, or niraparib.
sOMe CRpc treatMEntS are USed oNLY in mEn WHosE tUmors hAve certaIn chAraCteristIcs That mAke The thErApy more likelY To be effeCtiVe. men WhoSe tuMors express thE PrOTEiN psMa MaY reCeivE the RadiOpHArMaceutical lU-177 PSma, whIcH BinDs To anD destRoys Psma-Positive cellS. tHoSE Whose tuMors have defECTivE dnA damaGE rePair benEFit from tReaTMEnt witH the immune CHeckPoInT inhIbItOr dRug PembroLizUmaB And parp iNhIbiTOrS, naMElY olApArIb, rucaParib, oR nIrapaRib.